Telotristat Etiprate in a Subset of Carcinoid Syndrome Patients Who Have High Levels of Urinary 5-hydroxyindoleacetic Acid and Frequent Flushing

#1068

Introduction: Serotonin is a key mediator of carcinoid syndrome (CS). CS patients (pts) with high levels of urinary 5-hydroxyindoleacetic acid (u5-HIAA, a serotonin metabolite) and >3 flushing episodes/day are at increased risk of developing carcinoid heart disease (CaHD).

Aim(s): Telotristat etiprate (TE) is an oral inhibitor of serotonin synthesis in Phase 3 development for the treatment of CS. There is limited information on the potential benefits of serotonin reduction in CS pts who may be at higher risk for CaHD.

Materials and methods: We retrospectively reviewed data on all pts who received TE in a Phase 2 trial for CS. In pts with elevated baseline u5-HIAA and >3 flushing episodes/day, we assessed reductions in u5-HIAA, bowel movements (BMs) and flushing frequency while on TE.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Wheeler D

Authors: Wheeler D, Hörsch D, Valle J, Lapuerta P, Zambrowicz B,

Keywords: biomarker, carcinoid heart disease,